Experience with micronized progesterone in obstetric practice

Objective. To evaluate the linked properties, efficacy, and safety profile of Prajisun in various complications of pregnancy. Materials and methods. This prospective cohort study enrolled 49 women with a singlet pregnancy. The viscosity of progesterones was measured using a capillary viscometer (Fungilab) at various temperature conditions. Results. The viscosity of the most commonly used progesterones (Prajisun, Iprojin, and Utrojestan) was comparable. Thirty-six (73.4%) pregnant women used a drug vaginally; 8 (16.4%) had a combination drug (vaginally and orally); 5 (10.2%) took orally. The duration of therapy in each group was 62.0±10.2, 42.7±5.4, and 37.0±3.9 days, respectively. The oral administration of a drug was associated with impaired vaginal microbiocenosis. Eight (16.3%) patients had transient adverse events that occurred during the first week of drug use and did not require discontinuation of therapy. Pregnancy was successfully prolonged to full-term in 95.9%. There were no adverse neonatal outcomes in any case. Conclusion. Prajisun is an effective, safe, well-tolerated, and pathogenetically justified agent for luteal phase support in IVF cycles, for treatment of pregnant women with a threatened miscarriage, and for drug prevention of premature birth.

micronized progesterone, luteal support, threatened abortion, retrochorial hematoma, threatened premature birth, short cervix, a high risk for premature birth, drug tolerance, compliance